biote (BTMD) and Its Peers Head to Head Analysis

) is among 59 publicly traded companies in the Medicinals & Botanicals' industry. But how does it compare to its peers in this sector? We will compare Biote with similar companies on the basis of dividends, institutional owners, earnings, analyst ratings, profitability, valuation, and risk.


The table below compares the net margins of biote with those of its competitors, as well as their return on equity (ROE) and return on assets.

Net Margins

Return on Equity

Return on Assets





Biote competitors




This table compares Biote with its peers in terms of revenue, earnings per shares and valuation.

Gross Revenue

Net Income

Price to Earnings Ratio


$164.96 Million



Biote competitors

$282.87 Million

-$110.28 millions


Biote's competitors have a higher revenue but lower earnings. Biote's price-to-earnings is higher than that of its peers. This means it is more expensive.

Risk and Volatility

Biote's beta is 0.6. This means that its stock price has a 40% lower volatility than the S&P 500. Comparatively speaking, biote’s peers have a Beta of 1.16. This means that their average stock prices are 16% more volatile than S&P 500.

Institutional and Insider Ownership

Institutional investors hold 3.8% of Biote's shares. Comparatively 14.3% of the shares of all Medicinals & botanicals companies are owned by institutional investors. Biote's shares are owned by 16.6% company insiders. Comparatively 22,3% of shares in all 'Medicinals & botanicals companies' are held by insiders. A high level of institutional ownership indicates that hedge funds, endowments and large money managers are confident that a stock is likely to outperform the overall market in the long run.

Analyst Ratings has provided a list of biote's current rating and that of its competitors.

Sell Ratings

Hold Ratings

Buy Ratings

Strong Buy Ratings

Rating Score







Biote competitors






Biote currently has a consensus target price of $10.40. This suggests a potential upward movement of 82.94%. The 'Medicinals & Botanicals' group has a potential gain of 102.41%. Analysts believe that biote is less likely to grow than its peers, given the higher potential upside of biote's competitors.

You can read more about it here:

Biote is superior to its competitors in 7 out of 13 comparison factors.


Get Rating

biote Corp. is a medical practice building business in the hormone optimization area. The company provides a platform that allows Biote-certified doctors to prescribe bioidentical hormonal therapies, recommend dietary supplementation, and optimize hormone, vitamin and mineral imbalances. The company also sells Biote branded dietary supplement and sterile insertion kits for both men and women. offers a FREE daily email newsletter